

**REQUEST  
for  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

*Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000,  
provided for continued examination of a utility or plant application  
filed on or after June 8, 1995.*

*See the American Inventors Protection Act of 1999 (AIPA).*

Application Number	09/581,402
Filing Date	June 12, 2000
First Named Inventor	Tetsunori FUJISAWA et al.
Group Art Unit	1637
Examiner Name	Jeffery N. Fredman
Attorney Docket Number	2000-0562A
Confirmation No.	7196

**RECEIVED**  
MAR 04 2003  
TECHCENTER 1600 2900

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

**1. Submission required under 37 C.F.R. § 1.114**

**a. [X] Previously submitted:**

- i. ☒ Please enter and consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on November 27, 2002
- ii. ☐ Please consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other\_

**b. [X] Enclosed:**

- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other: Petition for a One Month Extension of Time, Version with Marking to Show Changes Made,

**2. Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required).

b. ☐ Other:

**3. Fees** (The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.)

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 23-0975.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☒ Extension of time fee (37 C.F.R. § 1.136 and § 1.17)
- iii. ☐ Other\_

b. ☒ Check in the amount of \$944.00 is enclosed

**4. CORRESPONDENCE ADDRESS**

**\*00513\***  
**000513**  
PATENT TRADEMARK OFFICE

By: \_\_\_\_\_

Lee Cheng  
Registration No. 40,949

WENDEROTH, LIND & PONACK, L.L.P.  
2033 "K" Street, N.W., Suite 800  
Washington, D.C. 20006-1021  
Phone: (202) 721-8200  
Fax: (202) 721-8250

February 27, 2003

02/28/2003 CSYHAB1 00000112 09561402

02 FC:1201  
03 FC:1201

750.00 DP  
64.00 DP

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

MAR 04 2003

RECEIVED

In re application of :  
Tetsunori FUJISAWA et al. : Docket No. 2000-0562A  
Serial No. 09/581,402 : Group Art Unit 1637  
Filed June 12, 2000 : Examiner J. Fredman  
NOVEL METALLOPROTEINASE INHIBITORS : Confirmation No. 7196

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,  
Washington, DC 20231

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Sir:

Attached hereto is a check in the amount of \$944.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time. . . . . \$110.00  
Request For Continued Examination (RCE). . . . . \$750.00  
Additional Claims Fee. . . . . \$ 84.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Tetsunori FUJISAWA et al.

By

Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
February 27, 2003


[Check No. 54451]

2000\_0562A

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 7196

Tetsunori FUJISAWA et al. : Docket No. 2000-0562A

Serial No. 09/581,402 : Group Art Unit 1637

Filed June 12, 2000 : Examiner J. Fredman

NOVEL METALLOPROTEINASE  
INHIBITORS

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

ADDITIONAL CLAIMS FEE TRANSMITTAL LETTER

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application. Additional fees required as a result of this Amendment are calculated as follows:

	SMALL ENTITY		LARGE ENTITY
Total Claims exceeding 20 (not already paid for): x	(\$ 9 = \$)	or	(\$18 = \$)
Indep. Claims exceeding 3 (not already paid for): 1 x	(\$42 = \$)	or	(\$84 = \$84)
<input type="checkbox"/> Multiple Dep. Claim(s) (if there previously were none): +	(\$140 = \$)	or	(\$280 = \$)
Total Additional Fee =	\$	or	<u>\$84.00</u>

- ☐ Small entity status of this application is established by the verified statement under 37 C.F.R. 1.9 and 1.27 which
- ☐ is enclosed or
- ☐ has been previously submitted.


- ☒ A check including the amount of \$84.00 is enclosed.

- [X] The Commissioner is authorized to charge any deficiency associated with this communication or to credit any overpayment to the Deposit Account. The original and two copies of this document are enclosed.

Respectfully submitted,

Tetsunori FUJISAWA et al.

By

  
Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
February 27, 2003